"Which health systems are providing low value care?": ift.tt/3DxXXKT

"2021 Nobel Prize in Economics goes to Card, Angrist and Imbens": ift.tt/3azKSUB

"The impact of public health efforts on US Mortality": ift.tt/3FRoRPy

"Friday Links": ift.tt/3p81NGo

"Center for Healthcare Economics and Policy brochure": ift.tt/3vpkab4

"The Pitfalls of Cost Sharing in Healthcare": ift.tt/3n3lU5S

"CMMI and its revised strategy": ift.tt/3js6TJX

"Part D Senior Savings Model: What is it?": ift.tt/3pvweGW

"Weekend Reading": ift.tt/3B2jp96

"Cato supports public option?": ift.tt/3ntT5Qh

"Characteristics of neighborhoods with high and low COVID-19 vaccination rates": ift.tt/2ZpShnP

"Mid-week reading": ift.tt/2ZBRIHt

"Vaccine hesitancy in low- and middle-income countries": ift.tt/3vVBhRV

"How much money should governments spend to incentivize the development of new antibiotics?": ift.tt/3nQigN7

"On behavioral change, health and age": ift.tt/3GIRNcX

"AHRQ’s research agenda for tackling patients with multiple chronic conditions": ift.tt/3BIc0vX

"Friday Links": ift.tt/3CNWNuJ

"Who won from rising insulin drug prices?": ift.tt/3BJKs9y

Today in Health, I join with coauthors, led by Jason Shafrin, in proposing that CMSGov implement an approach to move drug price negotiations towards a paradigm based on treatment value. tinyurl.com/yamdxjpb CEVR UW School of Pharmacy @SchaefferCenter ISPOR

x.com/i/broadcasts/1…